MétaCan
Menu
Back to cohort
Record W3141323837 · doi:10.1016/j.cjco.2021.03.001

Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors

2021· review· en· W3141323837 on OpenAlexafffund
Terry Lee, Alessandro Cau, Matthew P. Cheng, Adeera Levin, Todd C. Lee, Donald C. Vinh, François Lamontagne, Joel Singer, Keith R. Walley, Srinivas Murthy, David M. Patrick, Oleksa Rewa, Brent W. Winston, John K. Marshall, John H. Boyd, Karen C. Tran, André C. Kalil, Russell Mcculoh, Robert Fowler, James M. Luther, James A. Russell

Bibliographic record

VenueCJC Open · 2021
Typereview
Languageen
FieldMedicine
TopicCOVID-19 Clinical Research Studies
Canadian institutionsHealth Sciences CentreVancouver General HospitalUniversity of CalgaryUniversity of AlbertaUniversité de SherbrookeUniversity of TorontoBC Children's HospitalSt. Paul's HospitalSunnybrook Health Science CentreBC Centre for Disease ControlSt. Michael's HospitalCentre for Advancing Health OutcomesMcGill University Health CentreUniversity of British Columbia
FundersFonds de Recherche du Québec - SantéUniversity of British ColumbiaFerring PharmaceuticalsCanadian Institutes of Health ResearchInnovative Medicines Canada
KeywordsConfoundingAngiotensin Receptor BlockersMeta-analysisMeta-regressionAngiotensin-converting enzymeCoronavirus disease 2019 (COVID-19)Internal medicineMedicinePharmacologyChemistryDiseaseBlood pressure

Abstract

fetched live from OpenAlex

BACKGROUND: Angiotensin receptor blockers (ARBs) and/or angiotensin-converting enzyme (ACE) inhibitors could alter mortality from coronavirus disease 2019 (COVID-19), but existing meta-analyses that combined crude and adjusted results may be confounded by the fact that comorbidities are more common in ARB/ACE inhibitor users. METHODS: We searched PubMed/MEDLINE/Embase for cohort studies and meta-analyses reporting mortality by preexisting ARB/ACE inhibitor treatment in hospitalized COVID-19 patients. Random effects meta-regression was used to compute pooled odds ratios for mortality adjusted for imbalance in age, sex, and prevalence of cardiovascular disease, hypertension, diabetes mellitus, and chronic kidney disease between users and nonusers of ARBs/ACE inhibitors at the study level during data synthesis. RESULTS: In 30 included studies of 17,281 patients, 22%, 68%, 25%, and 11% had cardiovascular disease, hypertension, diabetes mellitus, and chronic kidney disease. ARB/ACE inhibitor use was associated with significantly lower mortality after controlling for potential confounding factors (odds ratio 0.77 [95% confidence interval: 0.62, 0.96]). In contrast, meta-analysis of ARB/ACE inhibitor use was not significantly associated with mortality when all studies were combined with no adjustment made for confounders (0.87 [95% confidence interval: 0.71, 1.08]). CONCLUSIONS: ARB/ACE inhibitor use was associated with decreased mortality in cohorts of COVID-19 patients after adjusting for age, sex, cardiovascular disease, hypertension, diabetes, and chronic kidney disease. Unadjusted meta-analyses may not be appropriate for determining whether ARBs/ACE inhibitors are associated with mortality from COVID-19 because of indication bias.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.021
metaresearch head score (Gemma)0.038
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: Meta-analysis
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.021
Threshold uncertainty score0.112

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0210.038
Meta-epidemiology (narrow)0.0040.002
Meta-epidemiology (broad)0.0170.080
Bibliometrics0.0070.007
Science and technology studies0.0010.001
Scholarly communication0.0040.002
Open science0.0030.002
Research integrity0.0030.003
Insufficient payload (model declined to judge)0.0040.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.364
GPT teacher head0.521
Teacher spread0.157 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations21
Published2021
Admission routes2
Has abstractyes

Explore more

Same venueCJC OpenSame topicCOVID-19 Clinical Research StudiesFrench-language works237,207